

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number
WO 02/11721 A1

(51) International Patent Classification⁷: **A61K 31/425**,
A61P 7/00 // (A61K 31/425, 31:155)

(21) International Application Number: PCT/EP01/08512

(22) International Filing Date: 24 July 2001 (24.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00/10362 4 August 2000 (04.08.2000) FR

(71) Applicant (for all designated States except US): **MERCK
PATENT GMBH** [DE/DE]; Frankfurter Strasse 250,
64293 Darmstadt (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MOINET, Gérard**
[FR/FR]; 15, rue Lamartine, F-91400 Orsay (FR). **BOT-
TON, Gérard** [FR/FR]; 9bis, rue du Haras, F-78530 Buc
(FR). **MESANGEAU, Didier** [FR/FR]; 5 rue Auguste
Renoir, F-77380 Combs La Ville (FR).

(74) Common Representative: **MERCK PATENT GMBH**;
Frankfurter Strasse 250, 64293 Darmstadt (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING METFORMIN AND A 5-PHENOXYALKYL-2,4-THIAZO-
LIDINEDIONE-TYPE DERIVATIVE

(57) Abstract: The present invention relates to a pharmaceutical composition comprising, as active ingredients, metformin option-
ally in the form of one of its pharmaceutically acceptable salts and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative.

WO 02/11721 A1

PHARMACEUTICAL COMPOSITION COMPRISING METFORMIN AND A 5-PHENOXYALKYL-2,4-THIAZOLIDINEDIONE-TYPE DERIVATIVE

The present invention relates to a pharmaceutical composition comprising, as active ingredients, metformin optionally in the form of one of its pharmaceutically acceptable salts and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative described in WO 97/47612.

Its subject is also the use of metformin optionally in the form of one of its pharmaceutically acceptable salts and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative for the preparation of a medicinal preparation intended to reduce hyperglycaemia, more particularly hyperglycaemia in non-insulin-dependent diabetes.

Metformin is mainly known for its antihyperglycaemic activity and is widely used in the treatment of non-insulin-dependent diabetes. In the case of non-insulin-dependent diabetes, metformin is also administered to the patient in combination with insulin, metformin being known to improve sensitivity to insulin.

Numerous 2,4-thiazolidinedione derivatives have been described as antihyperglycaemic and hypolipemic agents and thus described as antidiabetic agents (Takeda, patent EP 193 256 and Sankyo patent EP 207 581). These compounds are activators of the peroxisome proliferator activated receptor γ (PPAR γ).

The combination of some 2,4-thiazolidinedione derivatives and biguanide, more particularly metformin, for treating diabetes has already been described (Takeda, patent application EP 749 751 and Smithkline Beecham, patent application WO 98/57634).

Diabetes is a chronic disease exhibiting various pathological manifestations. It is accompanied by disorders in the metabolism of lipids and sugars, and by circulatory disorders. In many cases, diabetes tends to progress into various pathological complications. Thus, it is necessary to find the treatment adapted to each individual suffering from diabetes.

The specific combination of metformin optionally in the form of one of its pharmaceutically acceptable salts with 5-phenoxyalkyl-2,4-thiazolidinedione which has no activity on the transactivation of PPAR γ has

not been described and offers particular advantages, in particular the absence of weight gain and/or of haemodilution.

Thus, the aim of the present invention is to provide a composition which makes it possible to significantly improve the use of glucose.


Its aim is also to provide a composition suitable for the treatment of diabetes without having any effect on the secretion of insulin, but exhibiting activity on the metabolic insulin-resistance syndrome.

Its aim is finally to provide a composition which is particularly suitable for diabetics without hyperinsulinism.

These aims and others are achieved by the present invention which relates to a pharmaceutical composition comprising, as active ingredients, metformin optionally in the form of one of its pharmaceutically acceptable salts and a compound of formula (I), in combination with one or more pharmaceutically acceptable excipients.

This composition is particularly appropriate for treating diabetes, more particularly non-insulin-dependent diabetes. It is particularly suitable for reducing hyperglycaemia in non-insulin-dependent diabetes.

The compound of formula (I) is defined in the following manner:



in which A represents a linear or branched, saturated or unsaturated hydrocarbon group comprising from 2 to 16 carbon atoms,

D represents a homo- or heterocarbon-containing mono-, bi- or tricyclic aromatic structure which may include one or more heteroatoms,

X represents a substituent of the aromatic structure, chosen from hydrogen, an alkyl group having from 1 to 6 carbon atoms, an alkoxy group having from 1 to 6 carbon atoms, an alkoxyalkyl group in which the alkoxy and alkyl groups are as defined above, an aryl group defined as an

aromatic cyclic structure comprising one or two rings optionally including one or two heteroatoms in the ring, such as for example a phenyl or an α - or β -naphthyl, an arylalkyl group in which the alkyl group is as defined above and the aryl group is as defined above and optionally comprises one or more substituents, an arylalkylaryl group in which the arylalkyl and aryl fractions are as defined above, a halogen, a trifluoromethyl, a cyano, a hydroxyl, a nitro, an amino, a carboxyl, an alkoxy carbonyl, a carboxamide, a sulfonyl, a sulfone, a sulfonamide, a sulfamoyl, an alkylsulfonylamino, an acylamino, a trifluoromethoxy,

n is an integer ranging from 1 to 3,

with the restriction that if A represents a butyl radical, $(X)_n-D$ does not represent a 4-chlorophenyl group.

In the preceding text, among the aromatic radicals D, there may be mentioned as homocarbonyl-containing structure the phenyl, α -naphthyl, β -naphthyl, anthracene or fluorenyl radical. Among the heterocyclic aromatic radicals, there may be mentioned pyridyl, or the quinoliny or carbazoly ring.

D preferably represents a phenyl or naphthyl radical.

Among the alkyl groups having from 1 to 6 carbon atoms, there may be mentioned in particular a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl or hexyl radical. Among the alkoxy groups having from 1 to 6 carbon atoms, there may be mentioned a methoxy, ethoxy, propoxy, isopropoxy, butoxy or isobutoxy radical. Among the halogen groups, there may be mentioned in particular fluorine, chlorine, bromine or iodine.

The chain A is a linear or branched hydrocarbon chain having from 2 to 16 carbon atoms, which is saturated or which has one or more ethylenic unsaturations, optionally substituted with at least one hydroxyl radical or with a phenyl radical. As examples of a linear alkyl radical, there may be mentioned in particular a divalent ethyl, propyl, butyl, pentyl, hexyl, octyl, nonyl, decyl, dodecyl or hexadecyl radical. Among the branched alkyl chains, there may be mentioned in particular the divalent 2-ethylhexyl, 2-methylbutyl, 2-methylpentyl, 1-methylhexyl or 3-methylheptyl radical. Among the monohydroxyalkyl chains, the radicals having 2 or 3 carbon

atoms, such as 2-hydroxyethyl, 2-hydroxypropyl or 3-hydroxypropyl, are preferred. Among the polyhydroxyalkyl chains, the radicals having 3 to 6 carbon atoms and 2 to 5 hydroxyl radicals, such as 2,3-dihydroxypropyl, 2,3,4-trihydroxybutyl or 2,3,4,5-tetrahydroxypentyl or the pentaerythritol
5 residue, are preferred. Among the hydrocarbon chains having from 2 to 16 carbon atoms and having one or more ethylenic unsaturations, the divalent allyl radical may be mentioned in particular.

The divalent ethyl or propyl radical is preferred.

10

The present invention also relates to the tautomeric forms of the compounds of general formula (I), to the enantiomers, diastereoisomers and epimers of these compounds, and to their solvates.

15 It is possible to envisage that the ketone functional groups carried by the thiazolidine ring can become enolized and give rise to monoenols.

The thiazolidinedione derivatives may, in this case, be salified and may exist in the form of basic salts.

20

Examples of basic salts of the compounds of general formula (I) include pharmacologically acceptable salts, such as sodium salts, potassium salts, magnesium salts, calcium salts, amine salts and other salts of the same type (aluminium, iron, bismuth, and the like). The amine salts which are not
25 pharmacologically acceptable may serve as a means of identification, purification or resolution.

Among the compounds of general formula (I) according to the invention, there may be mentioned more particularly as compounds which are
30 currently preferred:

- 5-[3-(4-fluorophenoxy)propyl]thiazolidine-2,4-dione
- 5-(2-phenoxyethyl)thiazolidine-2,4-dione
- 5-[2-(4-fluorophenoxy)ethyl]thiazolidine-2,4-dione
- 5-[[1-hydroxy-2-(4-fluorophenoxy)]ethyl]thiazolidine-2,4-dione
- 35 - 5-[[2-hydroxy-3-(4-fluorophenoxy)]propyl]thiazolidine-2,4-dione
- 5-[1-methyl-2-phenoxyethyl]thiazolidine-2,4-dione
- 5-[2-(4-cyanophenoxy)ethyl]thiazolidine-2,4-dione (CRE 16336)
- 5-[2-(2-fluorophenoxy)ethyl]thiazolidine-2,4-dione
- 5-[2-(2-naphthyloxy)ethyl]thiazolidine-2,4-dione

and their pharmacologically acceptable salts.

These compounds have been described in patent application WO 97/47612.

5

It is preferable to use 5-[2-(4-cyanophenoxy)ethyl]thiazolidine-2,4-dione (CRE 16336).

10

According to the invention, metformin or 1,1-dimethylbiguanide may be administered in the form of one of its pharmaceutically acceptable salts such as the hydrochloride, acetate, benzoate, citrate, fumarate, embonate, chlorophenoxyacetate, glycolate, palmoate, aspartate, methanesulfonate, maleate, para-chlorophenoxyisobutyrate, formate, lactate, succinate, sulfate, tartrate, cyclohexanecarboxylate, hexanoate, octanoate, decanoate, hexadecanoate, octadecanoate, benzenesulfonate, trimethoxybenzoate, para-toluenesulfonate, adamantanecarboxylate, glycoxylate, glutamate, pyrrolidonecarboxylate, naphthalenesulfonate, glucose-1-phosphate, nitrate, sulfite, dithionate, phosphate, dobesilate, thioclate, hippurate, 3-benzamidopropanoate, glucuronate, L-pyrrolidone-5-carboxylate, cholate, α -glucose-1-phosphate, alginate, 4-aminobenzoate and the salt with chondriotinsulfuric acid.

25

Among these salts, the hydrochloride, fumarate, embonate and chlorophenoxyacetate are more particularly preferred.

30

The compositions of the invention contain therapeutically effective quantities of the various active ingredients. The ratios of the respective quantities of metformin and the compound of formula (I) therefore vary as a consequence.

35

Preferably, the weight ratio of metformin or of its pharmaceutically acceptable salt to the compound of formula (I) varies from 1/1, preferably 40/1, better still 2/1 to 20/1.

The compositions of the invention are preferably administered parenterally, or better still orally, other routes of administration not however being excluded, such as for example rectal administration.

5 When oral administration is envisaged, the compositions of the invention exist in the form of gelatin capsules, effervescent tablets, uncoated or coated tablets, sachets, sugar-coated tablets, oral solutions or ampoules, microgranules or prolonged-release forms.

10 When parenteral administration is envisaged, the compositions of the invention exist in the form of solutions and suspensions for injection packaged in ampoules or vials for slow venous infusion.

15 The forms for oral administration are prepared by mixing the active substance with various types of excipient or vehicle such as fillers, disintegrating agents, binders, colourings, flavour correctors and the like, followed by the forming of the mixture.

20 The colouring may be any of those authorized for a galenic use.

Examples of flavour correctors include cocoa powder, mint, borneol and powdered cinnamon.

25 As examples of binders, there may be mentioned polyvinylpyrrolidone, hydroxypropyl methyl cellulose, alginic acid, carbomer, carboxymethyl cellulose, dextrin, ethyl cellulose, starch, sodium alginate, polymethacrylate, maltodextrin, liquid glucose, magnesium and aluminium silicate, hydroxyethyl cellulose, ethyl cellulose, methyl cellulose and guar gum.

30 As disintegrating agent, it is possible to use alginic acid, sodium carboxymethyl cellulose, colloidal silicon dioxide, sodium croscarmellose, crospovidone, guar gum, magnesium and aluminium silicate, methyl cellulose, microcrystalline cellulose, potassium polacrinlin, powdered
35 cellulose, pregelatinized starch, sodium alginate and glycolate of starch and sodium.

Fillers are for example cellulose, lactose, calcium hydrogen phosphate and microcrystalline cellulose.

The tablets may be obtained in a conventional manner by compression of granules in the presence of one or more lubricants. Appropriate lubricants are calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, low-fat mineral oil, magnesium stearate, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate. These tablets may then be coated with polymers in solution or suspension, such as hydroxypropyl methyl cellulose or ethyl cellulose.

10

The granules used to do this are for example prepared using the wet granulation method from a mixture of the active ingredients with one or more excipients such as a binder, a disintegrating agent and a filler.

15 To obtain hard capsules, the mixture of active ingredients with an appropriate filler (for example lactose) is incorporated into empty gelatin capsules optionally in the presence of a lubricating agent such as magnesium stearate, stearic acid, talc or zinc stearate.

20 Soft capsules or gelatin capsules are prepared by solubilizing the active ingredients in an appropriate solvent (for example polyethylene glycol) followed by incorporation into soft capsules.

25 The forms for parenteral administration are obtained in a conventional manner by mixing active ingredients with buffers, stabilizing agents, preservatives, solubilizing agents, isotonicizing agents and suspending agents. In accordance with known techniques, these mixtures are then sterilized and then packaged in the form of intravenous injections.

30 As a buffer, persons skilled in the art may use buffers based on organic phosphate salts.

Examples of suspending agents include methyl cellulose, hydroxyethyl cellulose, acacia and sodium carboxymethyl cellulose.

35

Examples of a solubilizing agent include castor oil solidified with polyoxyethylene, polysorbate 80, nicotinamide or macrogol.

In addition, useful stabilizers according to the invention are sodium sulfite and sodium metasulfite, while there may be mentioned sodium p-hydroxybenzoate, sorbic acid, cresol and chlorocresol as preservatives. For the preparation of an oral solution or suspension, the active ingredients
5 are dissolved or suspended in an appropriate vehicle with a dispersing agent, a humectant, a suspending agent (for example polyvinylpyrrolidone), a preservative (such as methylparaben or propylparaben), a flavour corrector or a colouring.

10 For the preparation of suppositories, the active ingredients are mixed in a manner known per se with an appropriate base constituent such as polyethylene glycol or semisynthetic glycerides.

For the preparation of microcapsules, the active ingredients are combined
15 with appropriate diluents, appropriate stabilizers, agents promoting prolonged release of the active substances or any other type of additive for the formation of a central core which is then coated with an appropriate polymer (for example a water-soluble resin or a water-insoluble resin). Techniques known to persons skilled in the art will be used to this end.

20 The microcapsules thus obtained are then optionally formulated in appropriate dosage units.

The subject of the present invention is also the use of metformin optionally
25 in the form of one of its pharmaceutically acceptable salts in combination with a compound of formula (I) as defined above for the preparation of a medicinal combination intended for treating diabetes, more particularly non-insulin- dependent diabetes.

30 According to another of its aspects, the invention relates to the use of metformin optionally in the form of one of its pharmaceutically acceptable salts in combination with the said compound of formula (I) for the preparation of a medicinal combination intended for reducing hyperglycaemia in non-insulin-dependent diabetes.

35 The subject of the present invention is also a method for treating diabetes, more particularly non-insulin-dependent diabetes, in a mammal, comprising administering to the said mammal the composition according to the present invention.

Metformin may be provided in the form of any of the salts defined above; however, the use of metformin as it is or in the hydrochloride, fumarate, embonate or chlorophenoxyacetate form is preferred.

5

When metformin or its salt and the compound of formula (I) are incorporated into the same unit dose, the unit dose preferably comprises from 50 to 1 000 mg of metformin.

10 Advantageously, the unit dose comprises, in this case, from 12.5 to 50 mg of a compound of formula (I).

The dosage naturally depends on the mode of administration, the therapeutic indication, the age of the patient and their condition.

15

In general, the daily dosage varies between 100 and 2 000 mg of metformin and between 25 and 100 mg of compound of formula (I).

Concrete but nonlimiting examples of the invention will now be presented.

Example 1:

A tablet having the following composition is prepared:

5

Metformin	850 mg	77.3%
5-[2-(4-Cyanophenoxy)ethyl]thiazolidine-2,4-dione	50 mg	4.5%
Lactose	99 mg	9%
Hydroxypropyl cellulose	35 mg	3.2%
Sodium croscarmellose	55 mg	5%
Magnesium stearate	11 mg	1%

Example 2:

A tablet having the following composition is prepared:

10

Metformin	500 mg	80%
5-[2-(4-Cyanophenoxy)ethyl]thiazolidine-2,4-dione	25 mg	4%
Lactose	37.5 mg	6%
Hydroxypropyl cellulose	25 mg	4%
Sodium croscarmellose	31.25 mg	5%
Magnesium stearate	6.25 mg	1%

CRE 16336 AND METFORMIN COMBINATION
TEST FOR A BENEFICIAL EFFECT OF THIS
COMBINATION IN THE TREATMENT OF HYPERGLYCAEMIA

5 PHARMACOLOGICAL STUDY

The antidiabetic effect of the metformin and CRE16336 combination was studied on the nOSTZ rat, an experimental model of non-insulin-dependent diabetes.

10

This model is produced by intravenous injection of Streptozotocin (STZ) 100 mg/kg, on the day of birth.

The characteristics of this model are:

15

- a hyperglycaemia
- an absence of basal hypoinsulinaemia
- a glucose intolerance
- an absence of insulin resistance

20

➤ EXPERIMENTAL PROTOCOL

38 male nOSTZ rats were used after selection based on the hyperglycaemia value after fasting for 2 h in order to homogenize the groups.

25

They were then divided into 4 groups:

- a control nOSTZ group
- a group treated with metformin at 25 mg/kg
- 30 - a group treated with CRE16336 at 12.5 mg/kg
- a group treated with metformin 25 mg/kg and CRE16336 12.5 mg/kg

35

5 male Wistar rats were incorporated into this study in order to evaluate the degree of hyperglycaemia in the diabetic animals.

The products were administered orally in the morning between 8 am and 9 am, for 4 days. The glycaemia, insulinaemia and lacticaemia were determined, after 4 days of treatment, by collecting blood samples from the

tail of the rats anaesthetized beforehand, 2 h after the last administration of the products.

➤ RESULTS

5

	T0	4 DAYS		
	Glucose <i>mg/dl</i>	Glucose <i>mg/dl</i>	Lactate <i>mg/dl</i>	Insulin <i>μU/ml</i>
Control nOSTZ	221±5	169±6	11.5±1	37.0±7.3
Metformin 25 mg/kg	219±4	160±5	15.4±1.4	34.1±3.7
CRE16336 12.5 mg/kg	219±4	156±6	13.2±0.7	45.2±5.5
Metformin 25 mg/kg + CRE16336 12.5 mg/kg	221±4	138±6	14.7±0.5	44.4±4.3
Control Wistar	137±1	134±5	14.3±0.5	21.3±3.6

➤ COMMENTS

10 After 4 days of treatment (placebo), the glycaemia in the control nOSTZ rats reduces because of a "nursing" effect. The hyperglycaemia is however still present in these animals 169±6 vs 134±5 mg/dl in the Wistar rats.

The treatment with metformin or CRE16336 in very low dose does not modify the hyperglycaemia in the nOSTZ rats.

15

Unlike the monotherapy treatments, the combination of metformin and CRE16336, administered at ineffective doses, induces a significant reduction in the hyperglycaemia which regresses from 31 mg/dl (138±63 mg/dl vs 169±6 mg/dl in the control group).


20

The metformin and CRE16336 combination brings about normalization of the glycaemia at doses where, given separately, these 2 products are without effect on the hyperglycaemia.

25

CLAIMS

1. Pharmaceutical composition comprising, as active ingredients, (i)
 5 metformin optionally in the form of one of its pharmaceutically acceptable salts and (ii) a compound of formula (I) in combination with one or more pharmaceutically acceptable excipients, the compound of formula (I) being defined in the following manner:



10 in which A represents a linear or branched, saturated or unsaturated hydrocarbon group comprising from 2 to 16 carbon atoms,

15 D represents a homo- or heterocarbon-containing mono-, bi- or tricyclic aromatic structure which may include one or more heteroatoms,

X represents a substituent of the aromatic structure, chosen from hydrogen, an alkyl group having from 1 to 6 carbon atoms, an alkoxy group having from 1 to 6 carbon atoms, an alkoxyalkyl group in which the alkoxy and alkyl groups are as defined above, an aryl group defined as an
 20 aromatic cyclic structure comprising one or two rings optionally including one or two heteroatoms in the ring, such as for example a phenyl or an α - or β -naphthyl, an arylalkyl group in which the alkyl group is as defined above and the aryl group is as defined above and optionally comprises one or more substituents, an arylalkylaryl group in which the arylalkyl and aryl
 25 fractions are as defined above, a halogen, a trifluoromethyl, a cyano, a hydroxyl, a nitro, an amino, a carboxyl, an alkoxycarbonyl, a carboxamide, a sulfonyl, a sulfone, a sulfonamide, a sulfamoyl, an alkylsulfonylamino, an acylamino, a trifluoromethoxy,

30 n is an integer ranging from 1 to 3,

with the restriction that if A represents a butyl radical, $(X)_n$ -D does not represent a 4-chlorophenyl group.

2. Composition according to Claim 1, for treating diabetes.
3. Composition according to either of Claims 1 and 2, for treating non-insulin-dependent diabetes.
- 5 4. Pharmaceutical composition according to any one of Claims 1 to 3, characterized in that the weight ratio of metformin or of its pharmaceutically acceptable salt to the compound of formula (I) varies from 1/1 to 40/1.
- 10 5. Pharmaceutical composition according to any one of the preceding claims, characterized in that the metformin salt is a hydrochloride, fumarate, embonate or chlorophenoxyacetate.
- 15 6. Composition according to any one of the preceding claims, characterized in that the compound of formula (I) is chosen from:
 - 5-[3-(4-fluorophenoxy)propyl]thiazolidine-2,4-dione
 - 5-(2-phenoxyethyl)thiazolidine-2,4-dione
 - 5-[2-(4-fluorophenoxy)ethyl]thiazolidine-2,4-dione
 - 5-[[1-hydroxy-2-(4-fluorophenoxy)]ethyl]thiazolidine-2,4-dione
 - 20 - 5-[[2-hydroxy-3-(4-fluorophenoxy)]propyl]thiazolidine-2,4-dione
 - 5-[1-methyl-2-phenoxyethyl]thiazolidine-2,4-dione
 - 5-[2-(4-cyanophenoxy)ethyl]thiazolidine-2,4-dione
 - 5-[2-(2-fluorophenoxy)ethyl]thiazolidine-2,4-dione
 - 5-[2-(2-naphthyloxy)ethyl]thiazolidine-2,4-dione
 - 25 and their pharmacologically acceptable salts.
- 30 7. Composition according to Claim 6, characterized in that the compound of formula I is 5-[2-(4-cyanophenoxy)ethyl]thiazolidine-2,4-dione.
8. Composition according to any one of the preceding claims, which is appropriate for oral administration.
- 35 9. Use of metformin optionally in the form of one of its pharmaceutically acceptable salts in combination with a compound of formula (I) as defined in Claim 1, for the preparation of a medicinal combination intended for treating diabetes.

10. Use according to Claim 9, for the preparation of a medicinal combination intended for treating non-insulin-dependent diabetes.

11. Use according to either of Claims 9 and 10, characterized in that the metformin salt is a hydrochloride, a fumarate, an embonate or a chlorophenoxyacetate.

12. Use according to one of Claims 9 to 11, characterized in that the compound of formula (I) is chosen from:

- 10 - 5-[3-(4-fluorophenoxy)propyl]thiazolidine-2,4-dione
 - 5-(2-phenoxyethyl)thiazolidine-2,4-dione
 - 5-[2-(4-fluorophenoxy)ethyl]thiazolidine-2,4-dione
 - 5-[[1-hydroxy-2-(4-fluorophenoxy)]ethyl]thiazolidine-2,4-dione
 - 5-[[2-hydroxy-3-(4-fluorophenoxy)]propyl]thiazolidine-2,4-dione
 - 15 - 5-[1-methyl-2-phenoxyethyl]thiazolidine-2,4-dione
 - 5-[2-(4-cyanophenoxy)ethyl]thiazolidine-2,4-dione
 - 5-[2-(2-fluorophenoxy)ethyl]thiazolidine-2,4-dione
 - 5-[2-(2-naphthyloxy)ethyl]thiazolidine-2,4-dione
- and their pharmacologically acceptable salts.

20

13. Use according to any one of Claims 9 to 12, characterized in that the medicinal combination is provided in the form of a unit dose containing metformin or one of its pharmaceutically acceptable salts, and a compound of formula (I).

25

14. Use according to Claim 13, characterized in that the unit dose comprises from 50 to 1 000 mg of metformin and from 12.5 to 50 mg of a compound of formula (I).

30

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/08512

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/425 A61P7/00 //(A61K31/425, 31:155)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 03477 A (SMITHKLINE BEECHAM) 28 January 1999 (1999-01-28) claims 1,3,13	1,2,5
A	WO 98 57634 A (SMITHKLINE BEECHAM) 23 December 1998 (1998-12-23) cited in the application claims 1-3 page 2, line 25-30	1,2,5
A	M.RIDDLE: "Combining sulfonylureas and other agents" AMERICAN JOURNAL OF MEDICINE, vol. 108, no. suppl. 6A, 2000, pages 15S-22S, XP001002376 page 15S page 16S	1,2,5

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

6 December 2001

Date of mailing of the international search report

12/12/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Peeters, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/08512

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9903477	A	28-01-1999	AU 8448898 A	10-02-1999
			BG 104135 A	31-10-2000
			BR 9810445 A	05-09-2000
			CN 1264303 T	23-08-2000
			EP 1001783 A1	24-05-2000
			WO 9903477 A1	28-01-1999
			HU 0003629 A2	30-07-2001
			JP 2001510159 T	31-07-2001
			NO 20000228 A	17-01-2000
			PL 338126 A1	25-09-2000
			SK 592000 A3	12-09-2000
			TR 200000134 T2	21-09-2000
WO 9857634	A	23-12-1998	AU 8539398 A	04-01-1999
			BG 104060 A	31-10-2000
			BR 9810172 A	08-08-2000
			CN 1260716 T	19-07-2000
			WO 9857634 A1	23-12-1998
			EP 0996444 A1	03-05-2000
			NO 996266 A	17-12-1999
			PL 337362 A1	14-08-2000
			SK 179299 A3	07-11-2000
			TR 9903057 T2	21-04-2000
			HU 0002668 A2	28-12-2000